ArticleJournal of cancer survivorship : research and practice2026
Prostate cancer survivorship in modern times - insights into management of erectile dysfunction and urinary incontinence for clinically localized prostate cancer survivors in the United States.
Article in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDetermine factors associated with receiving erectile dysfunction (ED) and urinary incontinence (UI) treatment following therapy for clinically localized prostate cancer (PCa).
methodsPatients diagnosed with PCa (cT1-3N0M0) between 2015 and 2024 who were treated with radical prostatectomy (RP) and/or radiation therapy (RT) were identified in EPIC Cosmos. Patients receiving hormone monotherapy (HT), < 1 year follow-up, or incomplete data were excluded. ED and UI diagnoses and treatments were captured via CPT and ICD-10 codes. Cox multivariable regression adjusted for clinical and socioeconomic factors to identify treatment predictors, with sensitivity analyses among patients with baseline ED or UI.
resultsAmong 90,161 men, 39.29% developed ED, 33.35% received medical ED treatment (EDMT), and 0.99% underwent prosthesis (ST). UI occurred in 20.68% of patients, with 1.4% undergoing surgery (UIT). Black race (HR 1.50, p < 0.001) and prior ED (HR 1.41, p < 0.001) increased EDMT, while older age (HR 0.66, p < 0.001), higher social vulnerability (HR 0.85, p < 0.001), and RT-based therapy (RP + RT HR 0.75; RT + HT HR 0.39; RT HR 0.36; all p < 0.001) decreased EDMT. Prosthesis use was more likely among Black men (HR 2.03, p < 0.001), socially vulnerable patients (HR 1.86, p < 0.001), and those with prior ED (HR 2.06, p < 0.001), but less likely with older age (HR 0.61, p < 0.001) and RT-based therapy (RP + RT HR 0.63; RT + HT HR 0.18; RT HR 0.14; all p < 0.001). Prior UI (HR 2.08, p < 0.001) and social vulnerability (HR 1.25, p = 0.003) increased UIT, whereas RT (HR 0.08, p < 0.001) and RT + HT (HR 0.15, p < 0.001) reduced utilization. These disparities persisted among patients with baseline ED and UI.
conclusionsDespite a high prevalence of ED and UI following PCa treatment, surgical intervention remains uncommon (1%). Socioeconomic and clinical factors are significantly associated with treatment patterns, highlighting the need for improved pretreatment counseling and survivorship care. IMPLICATIONS OF CANCER SURVIVORS: Medical and surgical interventions for ED and UI are infrequently utilized. The differences in treatment frequency likely reflect not only variations in the underlying frequency, severity and patient preference, but also systemic, racial, and socioeconomic barriers. Prostate cancer survivors should actively advocate for their quality of life by initiating early discussions with their providers regarding all available functional recovery options. Furthermore, establishing equitable, culturally informed, and patient-centered survivorship pathways is vital to ensure all survivors receive the comprehensive care necessary to maximize their long-term outcomes.
Indexed as
Identifiers
42477303What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.